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Abstract: The body’s immune system has some capacity to recognize and attack cancerous 
growths, including prostate cancer. However, various intrinsic characteristics of tumor cells 
usually limit that capacity. Therapeutically administered immunologic stimuli, such as APC8015, 
an individualized, ex vivo stimulation of a patient’s own antigen presenting cells (APC), are 
capable of boosting the anti-tumor response. Late phase clinical trials of APC8015 (now also 
called Sipuleucel-T) show evidence of slowing disease progression and increasing survival in 
advanced prostate cancer. Such immunotherapeutic approaches hold real promise to provide 
additional useful and welcome weapons against this common malignancy.
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Therapeutic challenge and existing clinical practice
Prostate cancer (PC) was diagnosed in about 234,000 men and responsible for over 
27,000 deaths within the United in 2006 (Jemal et al 2006), while 219,000 cases and 
another 27,000 deaths are estimated for 2007 (Jemal et al 2007). Although deﬁ  ni-
tive therapy (surgery and/or radiation) can cure the majority of men with localized 
disease, some 20%–30% of treated men will relapse and a substantial fraction of 
these will succumb to this malignancy. Androgen-ablation therapy with luteinizing-
hormone-releasing hormone agonists and anti-androgens is the mainstay of treatment 
for such patients, but is not curative and eventually fails. After ﬁ  rst-line hormonal 
agents fail, additional hormone-modulating therapies are usually explored. When 
patients become truly hormone-refractory, taxane chemotherapy is the most accepted 
treatment. Docetaxol (Taxotere®)-based chemotherapy has proven survival beneﬁ  t, but 
can be too toxic for some patients and also is non-curative treatment (Tannock et al 
2004). Ultimately, unfortunately, these second and third-line hormonal therapies and 
chemotherapies fail and subsequent options for relapsed patients are limited, focusing 
primarily on palliative measures (Ross and Kantoff 2007). Consequently, there is a great 
need for newer, more effective yet relatively non-toxic systemic therapies for PC.
Immunologic or vaccine-type treatments have the potential, theoretically, to meet 
this need. The challenge with this type of therapeutic approach is to elicit and sustain a 
sufﬁ  ciently robust immunologic response to one’s own tumor cells, while leaving most 
other normal cells in the body unaffected. (Normal prostate cells are excluded here, 
because preservation of normal prostatic epithelium for PC patients is not necessarily 
a desirable thing). The main goal of immunologic treatments, therefore, is to provide 
therapeutic beneﬁ  t from the vaccination without creating a deleterious autoimmune 
response. This is inherently problematic given the “self-like” character of cancer cells. 
While they are clearly dysregulated physiologically and different histologically from 
the normal tissues cell from which they arise (epithelial cells in the case of prostatic Therapeutics and Clinical Risk Management 2008:4(1) 80
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carcinoma), tumor cells have an antigenic makeup that is 
difﬁ  cult to distinguish from that of their normal counterparts. 
PC cells in particular are generally considered to be poorly 
immunogenic (Saika et al 2004). Means have thus been 
sought to bolster the immune system’s ability to recognize 
features of PC cells which are unique and sufﬁ  ciently differ-
ent from normal cells, so as to overcome tumor tolerance.
Ways to stimulate the body’s own immune system to 
ﬁ  ght cancerous growths have long been sought and various 
methods have been explored and adopted over the past cen-
tury. Early efforts employed the instillation of inﬂ  ammatory/
immunogenic microbes into the tumor environment (Coley 
1893). Coley and others applied this strategy successfully 
against a number sarcomas and carcinomas over a century ago. 
Early stage, non-invasive bladder cancers are frequently 
treated today with such microbe-based therapy. Infusion of 
Bacille Calmette-Guerin (BCG) into the bladder elicits a 
nonspeciﬁ  c immune response which can control early bladder 
cancers (Karnes et al 2006). More recent efforts have focused 
on use of speciﬁ  c cytokines to stimulate immune recognition 
of cancer cells. Perhaps the best publicized attempts relate to 
investigations (reviewed in Rosenberg (2001)) at the NCI in 
the 1980’s. High-dose interleukin-2 (IL-2) and isolated tumor 
inﬁ  ltrating lymphocytes (TIL) cells and, later, low-dose IL-2 
and interferon showed some promise of controlling certain 
types of cancer, including renal cell carcinoma. The use of 
immunotherapies in urologic malignancies, therefore, has 
solid historical precedence, having been employed against 
kidney and bladder cancer for some time.
Developmental history
The newer vaccine therapies, such as APC8015, have been 
built upon the previous efforts mentioned above coupled 
with improved knowledge of the molecular regulators of 
immunity. Indeed, like most medical advances, develop-
ment of this vaccine therapy is the culmination of stepwise 
progress in several related areas of research. One area has 
been advances in understanding of antigen presenting cells 
(APC), their maturation and roles in immune surveillance and 
response to antigens. Another has been improved knowledge 
of cytokines and receptors regulating the immune response. 
Another has been technical improvements in identifying and 
isolating APC for therapeutic manipulation.
Antigen presenting cell
APC are key players in the immunologic response to target 
antigens, expressing costimulatory molecules as well as 
immune-activating cytokines (IL-12, GM-CSF, TNF-α, 
etc.) to elicit both primary and secondary immune responses 
(Saika et al 2004). APC can include activated B lymphocytes, 
monocytes, and macrophages, but dendritic cells (DC) are 
considered the most potent antigen presenters, capable of 
initiating anti-tumor responses from both naïve and memory 
T-cells (Karnes et al 2006). DC were ﬁ  rst described in 1973 
by Steinmann and Cohn. These investigators delineated 
cells in the spleen and lymph nodes of mice, which turned 
out to have extensive cytoplasmic process under light and 
electron microscopy. These cells were subsequently shown 
to internalize, process and then display foreign antigens to 
B and T lymphocytes and thus to be critical for priming 
cytotoxic T lymphocyte(CTL)-mediated immune response 
(Mayordoma et al 1997). By the mid-1990’s APC were being 
experimentally manipulated to treat PC in preclinical studies 
(Fong et al 1995).
In conjunction with the above studies, improvements 
in the identiﬁ  cation of APC and various categories of APC 
have also occurred (Wilkinson et al 2006). Advances have 
also been made in the techniques used to isolate, culture and 
expand APC/DC from human patients, such as density gradi-
ent centrifugation (Hsu et al 1996) and various leukapheresis 
methods (Mayordoma et al 1997).
GM-CSF
A number of protein factors have been identiﬁ  ed that regulate 
APC in both a positive and negative manner. Granulocyte 
macrophage colony stimulating factor (GM-CSF) was origi-
nally identiﬁ  ed and cloned because of its ability to stimulate 
white blood cell production in leukopenic patients. It was 
shown subsequently to be one of the most potent stimula-
tors of APC, enhancing their differentiation, survival, and 
possibly even antigen processing ability (Rini et al 2006 
and references therein). GM-CSF seems to have the most 
profound effects on DC functions (Sallusto et al 1994), 
compared to other factors, such as interferon-α, IL-12, and 
CD40 ligand (Klein et al 2000).
In preclinical studies, which utilized the Dunning rat 
model for PC, vaccination with GM-CSF gene-modiﬁ  ed 
tumor cells resulted in longer disease-free survival compared 
to untreated animals (Vieweg et al 1994). A preclinical study 
by Hurwitz et al (2000) in a transgenic mouse model for PC, 
using GM-CSF-augmented vaccination and another immuno-
modulator, yielded similar results. Stimulation of the immune 
system by exogenous GM-CSF has shown promise in clinical 
studies of several malignancies. Spitler et al (2000) reported 
its efﬁ  cacy as a single adjuvant agent against melanoma. 
Other clinical investigations with recombinant GM-CSF as Therapeutics and Clinical Risk Management 2008:4(1) 81
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a sole agent also showed evidence of beneﬁ  t in certain PC 
patients (Small et al 1999).
Pharmacology/immunology
Srivastava (2006) has pointed out the important distinction 
between prophylactic vaccination versus therapeutic vac-
cination. The former, of course, has been used extensively 
and extraordinarly successfully to combat infectious diseases 
around the world. The latter category, however, is more 
pertinent to the arena of oncological therapy and, unfortu-
nately, more difﬁ  cult to achieve. This difﬁ  culty arises from 
two-factors: ﬁ  rst is the innate ability of tumor cells to escape 
immunologic detection; the second is the need to elicit a 
sufﬁ  ciently robust cytotoxic response to a usually already 
well-established, substantial volume of disease (in contrast 
to the situation with prophylactic vaccination against a newly 
invading infectious organism). Mechanisms by which tumor 
cells escape from the body’s immune responses are several 
and include: (1) down regulation of the immune response 
by tumor cells themselves or by factors that they release; (2) 
altered expression of the major histocompatibility complex 
proteins by the tumor cells, impairing immune recognition; 
(3) altered expression of immunoregulatory factors and/or 
adhesion molecules by tumor or DC (eg, increased vascular 
endothelial growth factor (VEGF) expression); and (4) sub-
version of the immune response elements to actually facilitate 
tumor cell growth (Pawlec et al 2000; Karnes et al 2006).
As described earlier, central players in both the humoral 
and the cellular arms of the immune response are the APC, 
particularly the so-called DC. In the 1990’s, a number 
of different research groups reported success with DC 
manipulation to enhance antitumor immunologic response. 
DC are considered the most potent of the APC, capable of 
initiating T-cell-dependent immune responses from naïve 
T cells (Steinman et al 1991; Hart, 1997). Several immune-
activating cytokines are able to modulate DC function within 
the local tissue environment, including interferon-γ, TNF-α, 
IL-12 and GM-CSF (Mayordorma et al 2006). GM-CSF is 
a critical regulatory factor for several immune pathways 
(Schwaab et al 2006). It is a particularly potent stimulator 
of DC (Sallusto et al 1994). By the mid-1990’s, several 
investigators reported efficient tumor suppression and 
survival beneﬁ  t in mouse models, using GM-CSF-transduced 
tumor vaccines (Dranoff et al1993; Abe et al 1995). More 
recently, it was demonstrated that genetically modiﬁ  ed DC 
expressing GM-CSF elicit a speciﬁ  c cytotoxic T-cell response 
and therapeutic immunity in murine tumor models (Curiel-
Lewandrowski, 1999; Nakamura et al 2006).
For APC8015, the tissue-speciﬁ  c protein chosen by 
Dendreon as the target antigen for immunization was pros-
tatic acid phosphatase (PAP). Once utilized as a tumor marker 
for PC (before the advent of PSA), PAP is expressed in about 
95% of PC tumors, has fairly speciﬁ  c expression for prostatic 
tissue, and so was considered a good candidate for a prostate 
cancer-targeting antigen. To enhance its antigenicity and DC-
stimulating properties, PAP was linked to GM-CSF, using 
recombinant DNA techniques, producing a fusion protein 
termed PA2024. PA2024 thus consists of human PAP fused 
through its carboxy terminus to the amino terminus of human 
GM-CSF via a Gly-Ser linker. It is expressed in a Baculovirus 
system and puriﬁ  ed to  90% purity by a procedure that has 
been described (Burch et al 2000).
APC8015 (Sipuleucel-T) therefore consists essentially 
of an individual patient’s APC primed by exposure to 
PA2024. The ﬁ  nal vaccine product is produced by isolating 
an individual patient’s CD54-positive white cells via a leu-
kapheresis procedure, exposing the isolated cells ex vivo to 
PA2024, incorporating the stimulated cells into Dendreon’s 
proprietary antigen delivery cassette, and infusing the vac-
cine back into the patient intravenously. The vaccine is given 
on several different occasions, usually three times over a 
1-month period. APC8015 is thus comprised of autologous 
APC, but is a mixed cell suspension containing also mono-
cytes, macrophages, B and T cells, loaded with PA2024 
(Burch et al 2004).
Pharmacologically, the development of APC8015 entails 
some unique challenges. It is comprised of a recombinant 
antigenic protein which must be incubated with an individual 
patient’s isolated APC ex vivo. Thus, its preparation is a 
multi-step process that requires extraction of blood cells 
from the patient, transporting them to the vaccine manufac-
turer, incubating them with recombinant antigen, ensuring 
sterility of the processed cells, and returning them to the 
patient/doctor for infusion (Figure 1). The FDA has not 
approved a therapeutic cancer vaccine to date. Manufactur-
ing a product that is customized to each individual patient, 
with the consistency and purity demanded by the FDA, is a 
signiﬁ  cant hurdle to clear. In September 2003, however, the 
FDA designated APC8015 to an accelerated development 
program and subsequently granted the vaccine fast-track 
status in November 2005.
Animal/early human studies
A variety of preclinical studies with infused APC/DC, 
employing GM-CSF as a stimulatory factor and a tumor 
antigen for targeting, showed good efﬁ  cacy against various Therapeutics and Clinical Risk Management 2008:4(1) 82
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cancers in animal models. Improvement in both humoral 
(Flamand et al 1999) and cellular immune responses (Celluzzi 
et al 1996; Curiel-Lewandrowski et al 1999; Nakamura et al 
2002) occur with this vaccination strategy, though the later 
appears more critical. There are numerous published animal 
studies showing that speciﬁ  c CTL stimulation is facilitated 
by GM-CSF. Human studies have demonstrated this 
subsequently, also (Schwaab et al 2005). Mayordomo et al 
(1995) used ex vivo priming of DC with tumor-associated 
antigen in three different murine tumor models and showed 
Sipuleucel-T (Provenge®)Manufacturing Process
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excellent protection against tumor challenge in all, as well 
as an ability to eradicate pre-established tumors in two of 
the models.
Review of clinical studies to date
The ﬁ  rst Phase I clinical trial of Dendreons’s APC8015 was 
conducted at the Mayo Clinic between 1997–1998. This study 
enrolled 13 patients with hormone-refractory, metastatic PC, 
who were treated with APC8015 and then had several follow-
up injections of PA2024 alone. Treatment with APC8015 was 
tolerated well, with only mild (grade 1–2), transient episodes 
of fever, chills, myalgia, pain and fatigue reported. Three of 
these patients had a drop in their PSA level by 50% or more. 
All patients exhibited evidence of immunological response 
to treatment (Burch et al 2000). The next clinical trial with 
Dendreon’s APC8015 was a combined Phase I and II clinical 
study carried out in a group of 31 patients at the University 
of California, San Francisco, in the late 1990s. Again, all 
patients developed evidence of an immunologic response to 
the fusion protein PA2024 (Small et al 2000). However, only 
20% of patients exhibited evidence of a tumor response, as 
measured by a drop in PSA of 25% or more from baseline.
A second Phase II study was conducted by Burch et al 
(2004). This group at the Mayo Clinic investigated a slightly 
smaller cohort of 21 patients with hormone-refractory, meta-
static PC and found a transient PSA response in only 10% of 
participants. However, one of these was an individual who 
had a complete response radiographically, which was incred-
ibly durable, lasting more than 4 years. The treatment was 
again generally very well tolerated in both of these Phase II 
studies, with the most common adverse effects being mild, 
grade 1–2 rigors and fatigue.
The results from the early phase trials were sufﬁ  ciently 
promising to warrant further investigation in a randomized, 
controlled study. The ﬁ  rst Phase III study, designated D9901, 
was initiated in 2000 and enrolled 127 patients with asymp-
tomatic, metastatic, hormone-refractory PC from 19 centers. 
The trial was completed in 2005. This placebo-controlled 
study showed no signiﬁ  cant delay in time to disease progres-
sion (TTP) for the group as a whole (p-value = 0.061), but 
did demonstrate a signiﬁ  cance delay in TTP in a subset of 
patients who’s tumors had a Gleason score of  7 (a standard 
pathological grading scheme for PC ranging from 2 to 10). The 
secondary endpoint of the study, overall survival, also showed 
a signiﬁ  cant difference. In the ﬁ  nal three-year follow up of 
D9901, a median survival beneﬁ  t of 21 percent or 4.5 months 
(25.9 months for treated patients versus 21.4 months for 
placebo group; p-value = 0.01) and a three-fold improvement 
in survival fraction at 36 months (34% of treated patients 
alive versus 11% of placebo group; p-value = 0.01; hazard 
ratio = 1.7) were seen (Small et al 2006).
Meanwhile, a companion Phase III study called D9902 
had been started, which was a double-blinded, placebo-
controlled study in asymptomatic, metastatic hormone-
refractory PC patients. Ninty-eight patients were recruited 
by December 2002 when the study was halted due to the 
ﬁ  ndings in D9901 related to the Gleason score subgroups. 
The ﬁ  rst part of the study was then designated D9902A (the 
ﬁ  rst 98 patients enrolled without regard to Gleason score). 
The protocol was subsequently amended to focus on patients 
with Gleason score of  7 and continued as D9902B, again 
enrolling asymptomatic, metastatic hormone-refractory PC 
patients. This study began in July 2003, and is still underway, 
having an accrual target of 500 patients. The primary endpoint 
of D9902A, which again was TTP, did not show statistical 
signiﬁ  cance unfortunately (p-value = 0.033). An integrated 
analysis of D9901 and D9902A, however, did show a 
survival advantage in the overall intent to treat population 
(Srivastava 2006). Log rank analysis of the whole patient 
population showed a hazard ratio of 1.5 (p-value = 0.011) 
favoring treatment with APC8015. Proportional hazards 
regression (Cox) analysis also revealed a favorable hazard 
ratio of 1.8, with a p-value of 0.0006 (Hamawy 2006). In 
all human studies to date, the APC8015 treatment was well 
tolerated, with no dose-limiting toxicities observed (Small 
et al 2006). The main toxicities noted have continued to be 
mild, consisting of infusion-related, low-grade fever and 
chills lasting for one to two days.
In January 2007, Dendreon Corporation announced that 
the FDA accepted their application for a biologics license and 
assigned it priority review status. Priority review is granted to 
products that have potential to provide a signiﬁ  cant improve-
ment in the safety or effectiveness of the treatment, diagnosis 
or prevention of a serious or life-threatening disease. In March 
2007, an advisory committee to the FDA reviewed clinical 
safety and efﬁ  cacy data and voted in favor of both the safety 
and efﬁ  cacy of APC8015. However, in May 2007, the FDA 
decided that the available data was insufﬁ  cient for approval at 
that time (which has generated some controversy among PC 
advocacy groups). The agency has requested further clinical 
data to support the efﬁ  cacy claims in the Biologics License 
Application, as well as further information on the chemistry, 
manufacture and controls for APC8015 production. A ﬁ  nal 
decision by the FDA is thus still pending. Interim survival 
results from the ongoing Phase III study (D9902B) are 
expected by Dendreon sometime in 2008.Therapeutics and Clinical Risk Management 2008:4(1) 84
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Conclusions and future directions
The clinical trials with APC8015 to date indicate a 
moderate degree of immunological response that provides 
some therapeutic beneﬁ  t. The level of response, however, is 
not as robust in many patients, as might be hoped for. Addi-
tional data on the true magnitude of the response will become 
clearer as the latest Phase III trials mature. Nevertheless, it 
appears that additional manipulations of the immune system 
may be required to elicit the greatest potential beneﬁ  t from 
this immunological therapeutic approach. Subsequent clinical 
trials will probably focus on the combination of APC8015 
with other biologicals, especially additional immunoregula-
tory factors, to enhance the anti-tumor effect of the immune 
response. This has already begun with the investigation of 
Bevacizumab, a monoclonal antibody against VEGF, in 
combination with APC8015. Although originally developed 
because of its anti-angiogenesis properties, Bevacizumab 
(anti-VEGF) can also positively modulate the immune 
system, because VEGF has a negative (suppressive) regu-
latory effect on DC (Oyama et al 1998). This coordinated 
administration of anti-VEGF to patients receiving APC8015 
vaccine has potential to further enhance the immune stimula-
tion of the PA2024 primed dendritic cells. Indeed, a Phase II 
study of APC8015 in combination with bevacizumab among 
patients with hormone-dependent PC has been undertaken 
by the National Cancer Institute. Other combinations are 
undoubtedly under consideration and may include use of 
such recombinant stimulatory cytokines as IL-12 (Saika 
et al 2004), IL-2, Interferon, or anti-CTLA4 (CTLA4 is an 
endogenous dampening factor for APC and antibodies have 
been developed which inhibit its effects; Quezada et al 2006). 
Of course, other modulations of APC8015 therapy might also 
be investigated, including increased number of infusions, 
coordination with standard hormonal therapies, or combi-
nation with standard radiation or even chemotherapies. For 
instance, androgen ablation therapy has marked effects on 
the degree and the nature of T cell responses within prostate 
tissue and could possibly augment immunotherapeutics for 
PC (Mercader et al 2006).
Discernable progress has been made in the development 
of immunologic therapies for PC, but additional work lies 
ahead before the full potential of this therapeutic approach 
will be realized.
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